Equine Induced Pluripotent Stem Cells have a Reduced Tendon Differentiation Capacity Compared to Embryonic Stem Cells.
Authors: Bavin Emma P, Smith Olivia, Baird Arabella E G, Smith Lawrence C, Guest Deborah J
Journal: Frontiers in veterinary science
Summary
# Editorial Summary: Equine iPSCs and Tendon Differentiation Capacity Tendon injuries in horses typically heal through fibrosis and scarring, creating weak tissue prone to re-injury; stem cell therapy offers potential to regenerate functional tendon tissue instead. Bavin and colleagues compared equine embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs)—the latter being more accessible as they derive from adult tissues rather than embryos—by assessing their capacity to differentiate into tendon cells using both two-dimensional culture and three-dimensional tissue engineering approaches. Whilst iPSCs successfully expressed tendon-associated genes and proteins in 2D assays (particularly when treated with transforming growth factor-β3), they failed to generate functional tendon tissue in the more physiologically relevant 3D model, whereas ESCs did not show this limitation. The findings highlight that iPSCs, despite their practical advantages as an autologous cell source, currently lack the tendon differentiation capacity of ESCs, suggesting fundamental epigenetic or transcriptional differences between the two cell types. Before pursuing iPSC-based tendon therapies clinically, further characterisation of these cellular differences is essential to determine whether iPSCs can be modified to match ESC performance, or whether ESC-derived treatments remain the more viable near-term option for regenerative tendon medicine in horses.
Read the full abstract on PubMed
Practical Takeaways
- •iPSCs are currently not suitable for clinical tendon repair despite their advantage of being derived from adult tissues; ESCs remain superior for this application until iPSC differentiation can be improved
- •Results showing 2D success but 3D failure highlight the importance of using physiologically relevant 3D models when evaluating stem cell therapies—2D assays alone are insufficient
- •Further research into epigenetic programming of iPSCs is needed before they can be considered a viable clinical alternative to embryo-derived ESCs for tendon regeneration
Key Findings
- •Equine iPSCs expressed tendon-associated genes and proteins in 2D assays, particularly when enhanced with transforming growth factor-β3
- •iPSCs failed to differentiate into functional tendon cells and generate artificial tendons in 3D differentiation assays, unlike ESCs
- •3D in vitro tendon assays are more reliable than 2D assays for measuring true tendon differentiation capacity
- •Epigenetic differences between iPSCs and ESCs require further investigation before clinical application of iPSCs for tendon repair